Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune‐related lncRNA. (11th August 2021)

• Record Type: Journal Article
• Authors: Shen, Shuang; Chen, Xin; Hu, Xiaochi; Huo, Jinlong; Luo, Libo; Zhou, Xuezhi
• Is Part Of: Cancer medicine. Volume 10:Number 18(2021)
• Page Start: 6561
• Page End: 6575
• Publication Date: 2021-08-11
• Subjects: breast cancer -- immunotherapy -- LncRNA -- risk score -- TCGA -- tumor‐infiltrating immune; 616.994005
• DOI: 10.1002/cam4.4189
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: The composition of the population of immune‐related long non‐coding ribonucleic acid (irlncRNA) generates a signature, irrespective of expression level, with potential value in predicting the survival status of patients with invasive breast carcinoma. Methods: The current study uses univariate analysis to identify differentially expressed irlncRNA (DEirlncRNA) pairs from RNA‐Seq data from The Cancer Genome Atlas (TCGA). 36 pairs of DEirlncRNA pairs were identified. Using various algorithms to construct a model, we have compared the area under the curve and calculated the 5‐year curve of Akaike information criterion (AIC) values, which allows determination of the threshold indicating the maximum value for differentiation. Through cut‐off point to establish the optimal model for distinguishing high‐risk or low‐risk groups among breast cancer patients. We assigned individual patients with invasive breast cancer to either high risk or low risk groups depending on the cut‐off point, re‐evaluated the tumor immune cell infiltration, the effectiveness of chemotherapy, immunosuppressive biomarkers, and immunotherapy. Results: After re‐assessing patients according to the threshold, we demonstrated an effective means of distinguish the severity of the disease, and identified patients with different clinicopathological characteristics, specific tumor immune infiltration states, high sensitivity to chemotherapy, wellpredicted response to immunotherapy and thus a more favorable survival outcome. Conclusions: The current study presents novel findings regarding the use of irlncRNA without the need to predict precise expression levels in the prognosis of breast cancer patients and to indicate their suitability for anti‐tumor immunotherapy. Abstract : The manuscript is an immune‐related lncRNA pairing strategy to construct a risk assessment model. We did not use precise expression levels of the target lncRNAs in the signature.